Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate whether MM09, a sublingual immunotherapy, can help patients aged 12 to 65 with moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by house dust mites, with or without mild to moderate asthma. The trial is a phase III, randomized, double-blind, placebo-controlled study designed to assess if MM09 reduces symptoms and the need for rescue medications, while also monitoring safety. Participants will receive either the active MM09 sublingual spray or a placebo solution without the active ingredient. The treatment is given daily over 12 months. The study carefully compares the effects of MM09 against placebo to understand its impact on allergic rhinitisrhinoconjunctivitis and asthma symptoms. During the study, participants will record symptoms and medication use via a smartphone app. Researchers will measure combined symptom and medication scores, as well as separate scores for rhinitis, rhinoconjunctivitis, and asthma symptoms and medication intake during the last four weeks of treatment. Safety and any medical problems from inhaling MM09 will be closely monitored throughout the trial, which lasts up to 12 months.
Actively Recruiting
This research aims to analyze salvage treatment for patients with locally recurrent prostate cancer diagnosed through advanced imaging techniques such as choline PET, PSMA PET, and MRI, along with confirmed biopsy results. The study is observational and multicenter, focusing on patients who previously received radical-intent radiotherapy and are now scheduled for salvage treatment. The primary objective is to evaluate biochemical relapse-free survival and study the toxicities and quality of life impacts of this approach. Patients will undergo two fractions of high-dose-rate HDR brachytherapy as salvage treatment following initial radiotherapy. The salvage brachytherapy is part of routine clinical practice and is assessed through biochemical markers and imaging. Participants are followed for up to four years, with evaluations every six months to monitor treatment effects and disease status. During the study, participants will have regular assessments including imaging to detect local relapse, toxicity evaluations using standardized criteria, and quality of life questionnaires such as IPSS, FACT-P, and EORTC QLQ-PR25. Monitoring includes acute and chronic toxicity evaluations and tracking biochemical relapse-free survival for up to 48 months. The study involves a 2-year recruitment period with follow-up visits every six months over four years, ensuring ongoing observation of treatment outcomes and patient well-being.